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Head and Neck Squamous Cell Carcinoma (HNSCC) is the 6th most common
cancer globally and commonly presents with locally advanced disease, which has a
recurrence rate of around 50% despite aggressive multi-modality treatment involving
surgery, radiotherapy and chemotherapy or EGFR inhibition where appropriate. As
understanding of the underlying cancer biology and the complex interactions within the
tumor microenvironment improves, there is gathering interest in and evidence for the
role of immunomodulating agents in the management of HNSCC. Immune checkpoint
inhibitors, which aim to hinder the inhibitory interaction between programmed cell
death protein 1 (PD-1) and its ligand PD-L1, have demonstrated durable improvements
in patient outcomes in advanced / metastatic HNSCC, with both pembrolizumab
and nivolumab being granted FDA approval in 2016. There are numerous ongoing
clinical trials exploring the role of checkpoint inhibitors both as single agents and in
combination, administered with established treatment modalities such as chemotherapy
and radiotherapy, as well as alongside other novel immune modulators. These trials
are not limited to advanced / metastatic HNSCC, but also to the neo-adjuvant or
adjuvant settings. As studies complete and more results become available, the role
immunotherapy agents will have within the treatment strategies for HNSCCmay change,
with increasing biomarker selection resulting in personalized therapy aiming to further
improve patient outcomes.
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Head and neck cancer encompasses malignancies that arise in the paranasal sinuses, nasal cavity,
oral cavity, pharynx and larynx. In Europe, there are around 139,000 new cases of head and neck
cancer per year, 90% of which are squamous cell carcinoma (HNSCC) (1). While both smoking
and alcohol consumption have long been established as risk factors for the development of HNSCC,
human papillomavirus (HPV) has emerged as a driver for a significant proportion of oropharyngeal
squamous cell carcinomas and increasingly is being recognized as its own distinct clinical entity
with a more favorable prognosis than non-HPV associated HNSCC (2, 3).
The 2016 FDA approval of the Programmed death-1 (PD-1) monoclonal antibodies
pembrolizumab and nivolumab for the treatment of HNSCC heralded the dawn of a new era of
treatment for a patient population that historically has a 50% recurrence rate despite aggressive
multi-modality treatment involving surgery, radiotherapy, chemotherapy and, where appropriate,
EGFR inhibition (4).
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Intact immune surveillance is critical to control
carcinogenesis and in order to propagate locally and
metastasise cancer cells must develop mechanisms that
allow them to evade elimination by the host immune system.
Immunotherapy works on the premise that the host immune
system can be activated to overcome these acquired mechanisms,
allowing the recognition of cancer as non-self and eliminate
it.
In order for this to happen, T-lymphocytes must be able
to infiltrate the tumor and mount appropriate responses
(5) and higher numbers of CD3+, CD8+ and FOXP3+
tumor infiltrating lymphocytes (TILs) are associated with a
favorable outcome in in several malignancies, including HNSCC
(6). In particular, the presence of CD8+ “effector” T-cells
and the ratio between CD8+ and FOXP3+ regulatory T-
cells (Tregs) correlates with improved prognosis. Tregs are
known to actively suppress immune responses (7) and as
such their presence within the tumor microenvironment may
assist immune evasion in head and neck cancers. However,
further understanding is required as although their presence
is linked to a decreased survival in several tumor types, a
positive correlation has been reported in other cancers such
epithelial ovarian cancer, colorectal cancer and lymphoma
(8–10).
Some cancers evade T-cell directed immune effects
by developing ways of excluding the T-cells from the
tumor microenvironment. However, HNSCC has been
found to be one of the most immune-infiltrated cancer
types (11) suggesting other mechanisms are involved
and T-cell homing, infiltration and activity are under a
number of influences generated by the tumor. In HNSCC
several suppressive mechanisms have been identified that
include:
1. Deficiencies or alterations of tumor human leukocyte antigen
(HLA) class I molecules expression (12, 13) along with
overexpression of antigens causing T-cell tolerance (14)
2. Increases in immunosuppressive cytokines such Il-10, (15)
IL-6 (16), and TGF-β (17)
3. Aberrant activation of the transcription factors Signal
Transducers and Activators of Transcription 3 (STAT3) (18)
and NF-kB, (17) which are notably linked to IL-6 and TGF-β
signaling respectively.
To avoid autoimmunity a series of checkpoints exist on the
surface of immune cells, with the activation of a T-cell response
being a careful balance of co-inhibitory and co-stimulatory
molecules and their ligands (19) (Figure 1). In HNSCC
immunomodulatory agents exist that block interaction between
co-inhibitory receptors such as Cytotoxic T-Lymphocyte-
associated antigen 4 (CTLA-4), Programmed death-1 (PD-1)
or Lymphocyte activation gene-3 (LAG-3) and their ligands.
Conversely, biologics that mimic ligand activated signaling
in co-stimulatory molecules such as Glucocorticoid-induced
tumor necrosis factor receptor (GITR) have also been evaluated.
Both these approaches aim to achieve the same outcome; an
enhanced activation of an immune response to tumor cells
(Figure 2).
PD-1/PD-L1 AXIS
PD-1 is a member of the CD28 receptor family which is
expressed on activated T- and B-cells, monocytes and a subset of
thymocytes. The expression of PD-1 on activated T cells enhances
the suppressive function of Tregs and this effect is mediated by
the interaction with its ligands, PD-L1 and PD-L2, which are
expressed on antigen presenting cells, endothelial and epithelial
cells as well as on activated lymphocytes. The interaction between
PD-1 and PD-L1 negatively regulates immune responses by
decreasing cytokine production and inducing T lymphocyte
anergy and apoptosis. Upregulation of PD-L1 can occur in tumor
cells and allows cancer cells to escape from host immune systems
by functionally inactivating T-cell immune surveillance. The
inhibition of this interaction can enhance T-cell response and
mediate clinical anti-tumor activity (20, 21). Expression of PD-
L1 is often high in HNSCC tumors, with positivity being quoted
between 46 and 100% across several studies, this wide range likely
owing to differences in staining technique, sample preservation
and possibly sampling error (22).
Nivolumab is an IgG4 PD-1 monoclonal antibody designed
to block co-inhibitory signaling through the PD-1/PD-L1 axis.
Following early phase studies demonstrating promising data,
a phase III trial, CheckMate 141, compared nivolumab with
the physician’s choice of second line single agents (docetaxel,
methotrexate or cetuximab) in a 2:1 randomisation in patients
with platinum resistant recurrent / metastatic HNSCC. It
recruited 361 patients and response rates (RR) were low in
all arms, but higher in the nivolumab cohort (13.3%) with
6 complete responses (CR) and 26 partial responses (PR). In
the chemotherapy arm, RR was 5.8%, including 1 CR and 6
PR. The median overall survival (OS) was 7.5 months with
nivolumab, vs. 5.1 months in the control arm, and patients who
received nivolumab had a statistically significant 30% lower risk
of death (HR 0.70; 95% CI 0.51 to 0.96). There was also an
improvement in the estimated progression free survival (PFS) at 6
months; 19.7% with nivolumab and 9.9% for those who received
physician’s choice. This increased benefit at later time-points
gives promise to durable benefit for responding patients, as seen
with nivolumab in other tumor types where clinical data aremore
mature (23). In addition to the higher efficacy seen, treatment
with nivolumab was also more tolerable than the standard
therapies, with a reduction in grade 3 or 4 adverse events; 13.1 vs.
35.1% and a relative improvement in patient reported outcomes
(PROMS) and other Quality of Life parameters (24). Outcomes
of patients randomized to nivolumab who were Treated Beyond
Progression (TBP) were presented at the European Society of
Medical Oncology 2017 Annual Congress (ESMO 2017). Of
those patients who had progressed, 62 patients (42%) received
at least one further dose of nivolumab and of these 15 (24%)
had a subsequent reduction in target lesion size with 3 patients
achieving >30% reduction, with no increase in grade 3 or 4
toxicities (25). These findings of unusual patterns of response to
immune checkpoint inhibitors have also been described in other
patient groups (26, 27) and offers reassurance that continuing
therapy beyond progression is safe and may have a role to play
in patients maintaining clinical benefit.
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FIGURE 1 | Co-inhibitory and co-stimulatory checkpoints are a key element of T-cell immune regulation.
FIGURE 2 | Monoclonal antibodies to key co-inhibitory immune checkpoints.
Pembrolizumab, another IgG4 PD-1 antibody, has also been
examined as a treatment for patients with recurrent or metastatic
HNSCC. KEYNOTE-012 was a phase Ib study which included
an expansion cohort of 132 HNSCC patients. A response rate
of 18% at 9 months was reported (including 4 CR and 20 PR),
with a median OS of 8 months and a 6-month PFS of 23%.
Treatment was well tolerated with grade 3 or 4 toxicity reported
in 9% of patients (28) These data led to the accelerated approval
of pembrolizumab by the FDA. Outcomes from the confirmatory
phase III trial comparing pembrolizumabwith standard therapies
(KEYNOTE-040) in patients with platinum-resistant relapsed /
metastatic head and neck squamous cell cancers were also
presented at ESMO 2017 (29), although the final published
manuscript is awaited. This study was similar in design to the
CheckMate 141 study, although with a complex hierarchical
statistical analysis plan. It demonstrated a median OS of 8.4
months with pembrolizumab compared to 7.1 months in the
control arm, with a hazard ratio of 0.81 (95% confidence
interval 0.66–0.99), which did not reach statistical significance
(p = 0.020) within the multiplicity statistical model. The overall
survival data may have been confounded by some patients (12%)
within the control arm going on to receive immune checkpoint
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inhibitors post progression (cross-over effect). The evaluation
of other inhibitors of the PD-1/PD-L1 axis in HNSCC, such as
durvalumab, atezolizumab and avelumab, are currently ongoing.
GITR
GITR is a member of the Tumor Necrosis Factor superfamily,
expressed on the surface of CD25+ CD4+ Tregs. GITR
activation by its ligand (GITRL) reduces Treg recruitment and
abrogates their suppressive function (30, 31).
AMG228 is a IgG1 antibody that binds to GITR and recently
completed phase I clinical trial. Of the 30 patients treated, 10
had HNSCC. Of the 29 evaluable patients, none had an objective
response. Treatment-emergent toxicity was experienced in 90%
of patients; most common being hypophosphatemia, fatigue,
anemia, nausea and pyrexia. There was no evidence of altered
T cell activity observed despite complete target coverage in both
tumor and peripheral blood (32).
The promise of PD-1 inhibitors has been realized for a small
proportion of patients with advanced HNSCC. Further work
is ongoing, exploring mechanisms of primary and secondary
resistance to these agents within HNSCC, aiming to find better
predictive biomarkers and methods to increase likelihood for
response.
COMBINATION CHECKPOINT INHIBITION
Emerging evidence has implicated the upregulation of
alternative immune checkpoints in resistance to PD-1/PD-
L1 axis interruption (33). The use of combination checkpoint
inhibitors (CPI) has been successful in improving response rates
and survival in other tumor types, with an increasing number
of immune checkpoint inhibitors targeting many co-stimulatory
and co-inhibitory interactions transitioning from pre-clinical to
clinical evaluation in HNSCC.
CTLA-4 is commonly expressed on the surface of activated
T cells, where it binds to B7, preventing interaction with
co-stimulatory CD28, leading to negative regulation of T
cell proliferation and IL-2 production. Blockade of CTLA-4
correlates with an increase in T-Cell activation and maintenance
of high-frequency T-cell receptor clonotypes (34, 35). Dual
blockade of PD-L1 and CTLA-4 has been shown to improve
response rate and anti-tumor activity when compared to
monotherapy alone in metastatic melanoma (36) and the
combination is being explored in other solid cancers. In HNSCC,
this combination approach is being evaluated in four separate
trials (Table 1).
LAG-3 is expressed on the surface of activated CD4+ and
CD8+ T-cells and certain subtypes of natural killer and dendritic
cells. It is thought to negatively regulate T cell activation and
proliferation and is also expressed by Treg cells and required
for their optimal suppressive function (37–41). CA224-020 is a
phase I/IIa dose escalation and expansion study, exploring BMS-
986016 (an anti-LAG-3 antibody) alone and in combination
with Nivolumab in advanced solid tumors, including a HNSCC
cohort (NCT01968109). Data from the head and neck cohorts are
eagerly awaited.
CHECKPOINT INHIBITION IN
COMBINATION WITH OTHER IMMUNE
MODULATORS
The immune ecosystem is a complex network of interconnected
cells, cytokines and signaling pathways and as such augmenting
the antitumor effect of checkpoint inhibitors is not limited
to CPI combinations alone. As understanding of this complex
biology improves, a number of other agents with the potential
to modulate the tumor microenvironment are currently being
investigated for the treatment of HNSCC.
SCORES is a phase Ib/II trial of Durvalumab (a PD-L1
inhibitor) in combination with either AZD9150 or AZD5069
in advanced solid tumors including recurrent / metastatic
HNSCC (NCT02499328). AZD9150 inhibits STAT3, with pre-
clinical evidence of activity in lymphoma and lung cancer
(42). Pre-clinical studies have also shown that STAT3 inhibition
can increase chemo and radiotherapy sensitization in HNSCC,
particularly Nasopharyngeal Cancer (NPC) (43, 44). AZD5069
is a novel selective antagonist of CXC Chemokine receptor
2 (CXCR2), a G protein-coupled receptor for a number of
cytokines. It is overexpressed in HNSCC and is implicated in
disease proliferation via IL-8 signaling (45, 46). Initial results of
patients with HNSCC treated in the AZD9150 and Durvalumab
arm were announced at the ESMO Congress 2017. Of 35
patients, 15 had prior PD-L1 treatment and 20 were CPI-
naïve. In the CPI- naïve arm, a 25% objective RR was reported
(4 confirmed PR and 1 unconfirmed PR) with a 45% DCR at 12
weeks and 30% patients remaining on treatment at 25 weeks.
Overall the combination was felt to be tolerable, with G3/4
thrombocytopenia and increase in liver enzymes reported for
3.4% of those dosed, and two treatment related discontinuations
(unspecified). These early data are promising and mature results
are awaited. In the PD-L1 pretreated arm, 1 complete response
and 1 unconfirmed response were reported, with a 20% DCR at
12 weeks (47).
Indoleamine 2,3-dioxygenase 1 (IDO1) is a catabolizing
enzyme that induces immune tolerance by suppressing T-cells
and has been found to be associated with poor outcome in
laryngeal squamous cell carcinoma (48). IDO1 is being heavily
investigated as a novel target for immune therapies, with several
inhibitors in clinical development. KEYNOTE-037 is a phase
I/II study evaluating pembrolizumab given concurrently with
epacadostat, an oral inhibitor of IDO1. Patients with recurrent
/ metastatic HNSCC were eligible for this study if they had
received at least one line of platinum based chemotherapy and
were CPI-naïve. An interim update of this study was presented
at ASCO 2017, when data from 38 patients were presented,
36 of whom were efficacy-evaluable at this early cut off. An
ORR of 31% was reported, with a disease control rate of
58%, regardless of the number of previous lines of treatment.
The most common treatment related SAEs were fatigue (24%),
nausea (11%) and decreased weight (11%). These data suggesting
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TABLE 1 | Ongoing trials evaluating combination PD-L1 and CTLA-4 blockade in HNSCC.
Trial Phase Cohort Drugs Trial code
CheckMate 356 I/II EBV positive nasopharyngeal cancers, HPV positive
HNSCC
Ipilimumab and Nivolumab U111-1166-0687
CheckMate 714 II Recurrent or metastatic HNSCC Ipilimumab and Nivolumab vs. Nivolumab and
Placebo
NCT02823574
CheckMate 651 III First line treatment for HNSCC Ipilumumab and Nivolumab vs. Cetuximab with
platinum and flurouracil
NCT02741570
KESTERAL III Recurrent or metastatic HNSCC Durvalumab and Tremelimumab vs.
Durvalumab monotherapy
NCT02551159
Durvalumab, IgG1 antibody to PD-L1; EBV, Epstein-Barr Virus; Ipilimumab, IgG1 antibody to CTLA-4; Tremelimumab, IgG2 antibody to CTLA-4.
promising anti-tumor activity with good tolerability have led to
plans for a phase III study (49).
CHECKPOINT INHIBITION IN
COMBINATION WITH VIRAL THERAPY
Oncolytic viruses have been found to reduce tumor burden and
prime an anti-tumor immunity in a number of preclinical studies
(50, 51) and when used in combination with PD-1 inhibitionmay
overcome CPI resistance by broadening neoantigenome-directed
T-cell responses (52). Several oncolytic viruses are currently being
evaluated in HNSCC. KEYNOTE-137 is an ongoing phase Ib/III
randomized study exploring the combination of Talimogene
Laherparepvec (T-VEC) with pembrolizumab in recurrent
metastatic HNSCC (NCT02626000). T-VEC is a modified, live,
attenuated herpes simplex virus type 1 that is designed to
promote an antitumor response through selective replication
in tumor cells and production granulocyte macrophage colony-
stimulating factor (GM-CSF) to stimulate systemic antitumor
immunity. It has already been licensed as a single agent
for the treatment of unresectable metastatic melanoma after
demonstrating an improved durable response rate (DRR) and
mOS relative to GM-CSF (53, 54).
CHECKPOINT INHIBITION IN
COMBINATION WITH
CHEMORADIOTHERAPY
In addition to interest in combining immune checkpoint
inhibitors to other novel agents, there is also a rationale to
combine with both chemotherapy and radiotherapy, which are
both known to modulate the tumor microenvironment as well
as inducing immunogenic tumor cell death. There is particular
interest in exploring CPI in combination with chemo-radiation
in locally advanced head and neck cancers. Upregulation of
PD-L1 by tumor cells following administration of chemo-
radiotherapy (CRT) has been demonstrated in a number of
preclinical models (55–57) with an improvement in RR, PFS
and median time to death being achieved with the addition of
adjuvant durvalumab to CRT in locally advanced, unresectable
Non-Small-Cell Lung Cancer as demonstrated in the large phase
III PACIFIC study (58).
Higher numbers of CD3+ and CD8+ TILs have been shown
to positively correlate with clinical outcome to definitive CRT
in HNSCC (59). In addition, in a pilot study of 20 patients,
CRT was shown to alter the immune landscape in HNSCC,
with an increase in the number of CD8+ T effector cells,
CD4+ regulatory cells and T cells expressing PD1, TIM3 and
LAG3. It is important to note that in this study, most patients
were male (90%) with locally advanced human papillomavirus
(HPV) associated disease, 80% of which originated from the
oropharynx and thus results may not be representative of all
HNSCC entities (60).
A safety study demonstrating the tolerability of
pembrolizumab in addition to cisplatin-based CRT for locally
advanced HNSCC was presented at ASCO 2017. This 27-patient
study delivered a fixed dose of pembrolizumab 4–7 days prior to
CRT, 3 weekly for the duration of CRT and a further five doses
following completion. Patients predominantly had HPV positive
oropharyngeal tumors (74%) and all received their planned
RT dose, with 85% achieving target cisplatin dosing and 78%
completing the planned doses of pembrolizumab. The addition
of checkpoint blockade was not felt to significantly increase the
toxicity experienced by patients, however three patients did have
treatment discontinued due to immune related adverse events
(G2 peripheral motor neuropathy, G3 AST elevation and G1
Lhermitte-like syndrome). The study has now progressed into
expansion cohorts of both HPV positive and negative tumors to
confirm tolerance and gain preliminary evidence of efficacy (61).
Cetuximab is also used with RT for the radical treatment of
locally advanced HNSCC. It is an influencer of natural killer
cell response and consequently dendritic cell maturation (62,
63) and is thought to increase the expression of inhibitory
checkpoints PD-1, TIM-3 and CTLA-4 on TILs (64, 65). There
are a number of current trials attempting to determine the
benefit of checkpoint inhibition alongside varying combinations
of cetuximab and RT in locally advanced HNSCC, with the
combination with avelumab as part of REACH (NCT02999087)
being of particular interest due to the propensity of both
avelumab and cetuximab to activate the antibody-dependent
cellular cytotoxicity (ADCC) pathway (63, 66).
IMMUNE-RELATED ADVERSE EVENTS
Treatment with CPIs can have inflammatory side effects which
are termed immune related adverse events (irAEs). Although the
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exact mechanism is unknown, it is likely due to the role that
immune checkpoints have in maintaining immune homeostasis
and by inhibiting their action, T cells are able to react with
self-antigens, with different checkpoint inhibitors having distinct
immune toxicity profiles (67). These autoimmunemanifestations
are more common in patients with pre-existing autoimmune
disorders however they may still be safely administered to this
population if used with caution and appropriate patient selection
(68).
A pooled retrospective analysis of the safety profile of
nivolumab in 576 patients with advanced melanoma found
the 49% of patients had an irAE; most commonly skin,
gastrointestinal, endocrine and hepatic and were classed as
grade 3–4 in 4% of patients. The time of onset varied
depending on the organ system involved, with skin irAEs
manifesting at 5 weeks whereas renal toxicity had had median
time of onset of 15 weeks. Approximately 24% required
systemic immunosuppressive treatment with the majority of
cases resolving (69). In CheckMate 141, the side effect profile
of nivolumab in a HNSCC population showed lower rates of
both gastrointestinal and hepatic toxicities when compared to the
standard of care treatments but did demonstrated an increase in
skin toxicity (15.7%), endocrinopathies (7.6%) and pneumonitis
(2.1%) (24).
The results of a 114-case series of patients with metastatic
HNSCC treated with anti-PD-1 therapy was presented at ASCO
2018, demonstrating that patients who manifested an irAE had
improved outcomes compared to those that did not. In total,
59 irAEs were recorded in 49 patients with ORR being higher
in irAE positive group (30.6 vs. 12.3% p = 0.02) and an
improvement in both PFS (6.9 vs. 2.1 months; p = 0.0004) and
mOS (12.5 vs. 6.8 months; p = 0.007) were reported, which
remained significant on multivariate analysis (70). A similar
observation has been noted in patients withmetastatic melanoma
and persisted regardless if they required treatment with a
systemic immunosuppressant for treatment of their irAE (69).
The development of irAE’s can be serious and in some cases
fatal, and as such careful consideration must be taken before
initiating their use, particularly in the adjuvant or neo-adjuvant
setting. As our understanding of the mechanism that drive these
systemic manifestations improve, we may develop biomarkers
that help identify those who are more likely to develop them
which will assist in informed decision making and toxicity
monitoring.
BIOMARKERS
As improvements in the understanding of the interaction
between cancer and the host immunity are complimented by
increasing numbers of immunomodulatory drugs, there has
been a drive to develop potential biomarkers to select patients
most likely to benefit from treatment and assist in monitoring
response.
Both the nivolumab and pembrolizumab studies outlined
above explored the impact of HPV on outcome. In Checkmate-
141, OS appeared to be longer with nivolumab regardless of p16
status, however the increase was more pronounced in patients
with p16 positive tumors (mOS of 9.1 months with nivolumab
vs. 4.4 months with standard therapy) than in p16 negative
tumors (mOS 7.5 vs. 5.8 months respectively) (24). KEYNOTE-
012 also reported better outcomes in the patients with HPV-
positive tumors relative to HPV negative ones (RR 32% vs.
14%, 6 month PFS 37% vs. 20% and 6-month OS 70% vs. 56%
(28).
These trials also examined tumor cell PD-L1 expression
as a potential biomarker, with data suggesting increased
benefit in PD-L1 positive disease. In the overall survival
analysis of Checkmate-141, patients with PD-L1 expression
>1% treated with nivolumab had a hazard ratio for death
of 0.55 (95% CI 0.36–0.83) when compared to standard
therapy. Where PD-L1 expression was <1%, this HR was 0.89
(95% CI 0.54–1.45) (24). Similarly, KEYNOTE-012 reported
tumor PD-L1 expression using immunohistochemistry, with
positivity being defined as >1%. Patients with PD-L1 expression
>1% who received pembrolizumab had improved RR of
22 vs. 4% in those with PD-L1,1%, with median OS 303
vs. 151 days respectively (28). KEYNOTE-040 described an
OS HR of 0.54 (95% CI 0.35–0.82) with pembrolizumab in
patients with tumors with PD-L1 expression >50% but also
evaluated PD-L1 expression on both tumor and associated
immune cells (CPS score) describing OS HR of 0.75 for
PD-L1 CPS >1% with pembrolizumab compared to control
patients.
Of the 61 PD-L1 positive HNSCC in KEYNOTE-012,
43 had RNA expression profiling and survival data were
evaluated with multi-gene expression signatures that had
previously been derived in melanoma patients. Of these
signatures, the 6-gene INF-γ was the top-performing, with
significant associations to OR (p = 0.005) and PFS (<0.001).
On evaluation of the individual signature genes, INF-γ
inducible MHC-II expression was felt to be the biological
link. Using an optimal cutoff for INF-γ, positive predictive
value for response was 40% with a negative predictive
value of 95%; AUC = 0.8 (95%CI 0.61–0.95) within this
patients population, which may assist in identifying clinical
benefit from anti-PD-1 therapy in patients who are PD-L1
positive (71).
The somatic mutational load (ML) and INF-γ gene
expression profile were found to be independently predictive
of response to pembrolizumab in the 73 patients within
KEYNOTE-012 who had HPV and Epstein-Barr Virus (EBV)
negative HNSCC, with ML and INF-γ gene expression
profile being significantly associated with OR (p = 0.064
and p = 0.001; AUROC 0.82 and 0.74 respectively). The
INF-γ gene expression profile also remained a significant
predictor in HPV and EBV positive patients showing
promise as a predictor of response regardless of viral status
(72).
Combinations of these biomarkers may give additive value to
patient selection for CPI therapy. Other potential biomarkers that
have shown promise include epigenetic modification of genes
associated with homologous recombination, such as RAD51 and
XRCC3, which are thought to alter checkpoint expression (73)
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and the identification of different HNSCC subtypes, each with a
distinct tumor microenvironment (74) but how these influence
survival or response to immunotherapy has yet to be addressed.
CONCLUSION
Immunotherapy looks set to revolutionize the treatment of
HNSCC, with the approval of nivolumab and pembrolizumab
(FDA) already offering new therapeutic options in recurrent /
metastatic disease. As our knowledge of the biological processes
driving HNSCC improves, along with greater understanding of
the important features of the tumor microenvironment, so too
does the rationale for combination strategies and the parallel
development of predictive biomarkers. These approaches should
support an era where a personalized approach to immunotherapy
treatment translates into improved outcomes for patients with
this disease.
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